POZEN, Inc.

Co-Founder & Vice Chairman of the Board at Aralez Pharmaceuticals, Inc.

Canaan Management focuses on investments primarily in the technology and healthcare sectors. In the technology sector, the firm focuses on digital media, communications, mobility, enterprise software and clean technology. Within the healthcare sector, Canaan Partners focuses on investments in biopharmaceuticals, medical devices and diagnostics. Canaan Partners also invests technology-based Indian companies in the following sectors: consumer Internet, digital media, mobile and enterprise and managed services. In Israel, the firm seeks to invest in the development of early-stage companies in the following areas: (1) consumer Internet and digital media (2) communications infrastructure (3) enterprise software (4) clean technology and (5) medical device technologies.

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach, aiming to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. In addition to global equity and fixed income funds, Bellevue AM successfully manage multi-asset funds. A diverse family of ETF strategies (asset allocation with ETFs) rounds out the holistic profile. The firm’s in-house capital market research specialists systematically identify the most attractive asset classes, markets and sectors, as viewed from a holistic perspective. Their flagship investment vehicle, BB Biotech AG invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. BB Biotech’s investment portfolio usually consists of 20 up to a maximum of 35 biotechnology companies. There are established, large-cap companies as well as small- and mid-cap companies in the portfolio. The asset classes available to BB Biotech are direct investments in the shares of listed companies, equity interests in unlisted companies, corporate bonds, and options on a range of underlying assets. Bellevue AM invests almost exclusively in stocks for liquidity and risk/return reasons. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Corporate bonds are an alternative primarily when stock market trends are negative. Options on the stocks of portfolio companies will be bought and sold at opportune times and as a means of hedging currency exposure.